The partners have ended their collaboration on anti-influenza antibodies, freeing Vir to “actively” pitch the candidates to other companies while continuing to work with GSK on different respiratory pathogens.

https://www.fiercebiotech.com/biotech/gsk-vir-end-flu-drug-alliance-removing-key-piece-345m-pact